We provide you with 20 years of free, institutional-grade data for CVAC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CVAC. Explore the full financial landscape of CVAC stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CVAC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
CureVac N.V(NASDAQ:CVAC) 
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy an...
Website: https://www.curevac.com/
Founded: 2000
Full Time Employees: 500
CEO: Franz-Werner Haas
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends